|
1
|
Armeno M, Verini A, Del Pino M, Araujo MB,
Mestre G, Reyes G and Caraballo RH: A prospective study on changes
in nutritional status and growth following two years of ketogenic
diet (KD) therapy in children with refractory epilepsy. Nutrients.
11(1596)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
McGovern RA, Banks GP and McKhann GM:
Responsive stimulation in the management of medically refractory
epilepsy. In: Epilepsy Surgery and Intrinsic Brain Tumor Surgery.
Fountas K and Kapsalaki E (eds). Springer, Cham, pp205-211,
2019.
|
|
3
|
Sirven JI, Pedley TA and Wilterdink JL:
Evaluation and management of drug-resistant epilepsy. UpToDate.
https://www.uptodate.com/contents/evaluation-and-management-of-drug-resistant-epilepsy.
Accessed August 13, 2018.
|
|
4
|
Mishra S: Refractory epilepsy in children:
A short review. South Asian Res J Med Sci. 1:24–29. 2019.
|
|
5
|
Nigro SE: The efficacy of neurofeedback
for pediatric epilepsy. Appl Psychophysiol Biofeedback. 44:285–290.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Moosa ANV: Antiepileptic drug treatment of
epilepsy in children. Continuum (Minneap Minn). 25:381–407.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Golyala A and Kwan P: Drug development for
refractory epilepsy: The past 25 years and beyond. Seizure.
44:147–156. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Balagura G, Iapadre G, Verrotti A and
Striano P: Moving beyond sodium valproate: Choosing the right
anti-epileptic drug in children. Expert Opin Pharmacother.
20:1449–1456. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fu J, Peng L, Wang W, He H, Zeng S, Chen
TC and Chen Y: Sodium valproate reduces neuronal apoptosis in acute
pentylenetetrazole-induced seizures via inhibiting ER stress.
Neurochem Res. 44:2517–2526. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Brown C and Smith C: Sodium valproate.
Pract Diabetes. 35:186–187. 2018.
|
|
11
|
Çavuş I, Romanyshyn JC, Kennard JT,
Farooque P, Williamson A, Eid T, Spencer SS, Duckrow R, Dziura J
and Spencer DD: Elevated basal glutamate and unchanged glutamine
and GABA in refractory epilepsy: Microdialysis study of 79 patients
at the yale epilepsy surgery program. Ann Neurol. 80:35–45.
2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Johannessen Landmark C and Patsalos PN:
Drug interactions involving the new second- and third-generation
antiepileptic drugs. Expert Rev Neurother. 10:119–140.
2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Reimers A: Lamotrigine, bipolar disorder,
and the pill-free week. Bipolar Disord. 21:372–373. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yasam VR, Jakki SL, Senthil V,
Eswaramoorthy M, Shanmuganathan S, Arjunan K and Nanjan MJ: A
pharmacological overview of lamotrigine for the treatment of
epilepsy. Expert Rev Clin Pharmacol. 9:1533–1546. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Poolos NP, Castagna CE, Williams S, Miller
AB and Story TJ: Association between antiepileptic drug dose and
long-term response in patients with refractory epilepsy. Epilepsy
Behav. 69:59–68. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lanteaume L, Guedj E, Bastien-Toniazzo M,
Magalahaes A, Mundler O and Bartolomei F: Cognitive and metabolic
correlates of emotional vulnerability in patients with temporal
lobe epilepsy. J Neurol Neurosurg Psychiatry. 83:522–528.
2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ollenberger GP, Byrne AJ, Berlangieri SU,
Rowe CC, Pathmaraj K, Reutens DC, Berkovic SF, Scheffer IE and
Scott AM: Assessment of the role of FDG PET in the diagnosis and
management of children with refractory epilepsy. Eur J Nucl Med Mol
Imaging. 32:1311–1316. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hornbeck PV: Enzyme-linked immunosorbent
assays. Curr Protoc Immunol. 110:2.1.1–23. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ramaratnam S, Panebianco M and Marson AG:
Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane
Database Syst Rev: CD001909, 2016.
|
|
20
|
Verrotti A, Iapadre G, Di Donato G, Di
Francesco L, Zagaroli L, Matricardi S, Belcastro V and Iezzi ML:
Pharmacokinetic considerations for anti-epileptic drugs in
children. Expert Opin Drug Metab Toxicol. 15:199–211.
2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Pagura JR and Alessi R: Epilepsy and
seizures. In: The Sports Medicine Physician. Piedade SR, Imhoff AB,
Clatworthy M, Moises Cohen M and Espregueira-Mendes J (eds).
Springer Cham, pp235-240, 2019.
|
|
22
|
Hernan AE and Holmes GL: Antiepileptic
drug treatment strategies in neonatal epilepsy Elsevier. Prog Brain
Res. 226:179–193. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Li Q, Li QQ, Jia JN, Cao S, Wang ZB, Wang
X, Luo C, Zhou HH, Liu ZQ and Mao XY: Sodium valproate ameliorates
neuronal apoptosis in a kainic acid model of epilepsy via enhancing
PKC-dependent GABAAR γ2 Serine 327 phosphorylation. Neurochem Res.
43:2343–2352. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Rosenberg EC, Patra PH and Whalley BJ:
Therapeutic effects of cannabinoids in animal models of seizures,
epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Epilepsy Behav. 70B:319–327. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Han SA, Yang EJ, Song MK and Kim SJ:
Effects of lamotrigine on attention-deficit hyperactivity disorder
in pediatric epilepsy patients. Korean J Pediatr. 60:189–195.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Korley FK, Diaz-Arrastia R, Wu AHB, Yue
JK, Manley GT, Sair HI, Van Eyk J, Everett AD, Okonkwo DO, Valadka
AB, et al: TRACK-TBI investigators: Circulating brain-derived
neurotrophic factor has diagnostic and prognostic value in
traumatic brain injury. J Neurotrauma. 33:215–225. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Bathina S and Das UN: Brain-derived
neurotrophic factor and its clinical implications. Arch Med Sci.
11:1164–1178. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tan XH, Song ZB, Wang H, Wang Q and He JL:
Influence of adjuvant levetiracetam therapy on serum nerve
cytokines and apoptosis molecules in patients with refractory
partial epileptic seizure. Hainan Yixueyuan Xuebao. 23:145–149.
2017.(In Chinese).
|
|
29
|
Skaper SD: Nerve growth factor: A
neuroimmune crosstalk mediator for all seasons. Immunology.
151:1–15. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tuszynski MH, Yang JH, Barba D, U HS,
Bakay RA, Pay MM, Masliah E, Conner JM, Kobalka P, Roy S, et al:
Nerve growth factor gene therapy: Activation of neuronal responses
in Alzheimer disease. JAMA Neurol. 72:1139–1147. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Silveira DC, Holmes GL, Schachter SC,
Geula C and Schomer DL: Increased susceptibility to generalized
seizures after immunolesions of the basal forebrain cholinergic
neurons in rats. Brain Res. 878:223–227. 2000.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang F, Lin Y, Kang D, Chen F, Lin K and
Su X: Distribution and expression of brain-derived neurotrophic
factor, nerve growth factor, and neurotrophic factor-3 in
refractory epilepsy-associated focal cortical dysplasia. Clin
Neuropathol. 36:233–239. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
33
|
Alpdemir M, Özcan O, Alpdemir MF, Şeneş
M, Azak A, Duranay M and Yücel M: Serum neuron specific enolase
and S-100B levels in hemodialysis and peritoneal dialysis patients.
Eur Arch Med Res. 35:83–87. 2019.
|
|
34
|
Shaik AJ, Reddy K, Mohammed N, Tandra SR,
Rukmini Mridula Kandadai and Baba Kss S: Neuron specific enolase as
a marker of seizure related neuronal injury. Neurochem Int.
131(104509)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Calik M, Abuhandan M, Kandemir H, Güzel B,
Solmaz A, Celik H, Taskin A and Iscan A: Interictal serum S-100B
protein levels in intractable epilepsy: A case-control study.
Neurosci Lett. 558:58–61. 2014.PubMed/NCBI View Article : Google Scholar
|
